**Core Concept**
CD34 is a transmembrane glycoprotein that serves as a marker for hematopoietic progenitor cells. It plays a crucial role in the regulation of cell adhesion, migration, and proliferation. CD34 is expressed on the surface of early hematopoietic stem cells, as well as on endothelial cells and other cell types.

**Why the Correct Answer is Right**
The correct answer is related to the use of CD34 as a tumor marker for acute myeloid leukemia (AML) and other hematological malignancies. CD34 expression is typically upregulated in AML cells, making it a useful marker for diagnostic and prognostic purposes. The mechanism behind CD34's role in AML involves its interaction with other cell surface molecules, such as CD33, which contributes to the adhesion and migration of leukemic cells.

**Why Each Wrong Option is Incorrect**
**Option A:** CD34 is not a tumor marker for breast cancer. While breast cancer cells can express various surface markers, CD34 is not a commonly used marker for this disease.

**Option B:** CD34 is not a tumor marker for lung cancer. Lung cancer cells can express a variety of surface markers, but CD34 is not typically associated with this disease.

**Option C:** CD34 is not a tumor marker for lymphoma. While lymphoma cells can express various surface markers, CD34 is not a commonly used marker for this disease.

**Clinical Pearl / High-Yield Fact**
It's essential to differentiate between CD34 and CD33, as these markers are often used together to diagnose and manage AML. CD33 is a myeloid cell surface antigen that can be targeted with specific therapies, whereas CD34 is primarily used as a diagnostic marker.

**Correct Answer: D.** CD34 is used as a tumor marker for acute myeloid leukemia (AML) and other hematological malignancies.